ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, ...

Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease, affecting up to one in three people in the general population, with an ...

An enzyme found in papaya could lead to new medicines: a scientific review reveals the surprising pharmaceutical potential of ...

An injection that blocks the activity of a protein involved in aging reverses naturally occurring cartilage loss in the knee ...

Highlighting 10 innovative late-stage BioPharma drugs with the potential to reshape treatment paradigms and industry dynamics ...

Jyong Biotech advances plant-derived carotenoid drugs with MCS-2 for BPH and early programs like MCS-8 showing signals as ...

Emerging evidence suggests there may be a critical window for estrogen therapy to protect against cognitive decline later in ...

Three cancer therapies were among the first two batches of drugs to receive vouchers through a new FDA program.

The younger that someone is when certain illnesses hit, especially before puberty, the more severe symptoms may be. And while ...

Orthotics and exercise outperform medication: simple therapies offer greater relief for knee osteoarthritis with fewer risks.

The Veterans With ALS Reporting Act seeks to develop strategies for lowering the potential risks for ALS, commonly known as ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.